Robert Israel, MD

Robert Israel, M.D., graduated with a BA in English and Anthropology from Harvard College, an MD from the University of Pennsylvania School of Medicine, and a residency in Obstetrics and Gynecology at The Johns Hopkins Hospital. He completed a post-residency, two-year obligation to the US Navy in the Department of Obstetrics and Gynecology at Balboa Naval Hospital in San Diego, California, where he established the first Infertility Clinic. He joined the new, full-time Department of Obstetrics and Gynecology at the University of Southern California (USC) School of Medicine in late 1969, and has remained a faculty member at that institution ever since, achieving professorial level. He has been a member of the department’s Executive Committee, since its inception in 1970. For over 25 years, he was the director of the department’s required medical student rotation. He chaired the division of gynecology at two different times for over 10 years. From 2005 -2007, he was the first director of development for the department. During that time period, he initiated two endowed department chairs and helped convert the department’s former resident organization into a significant alumni association. Presently, he is the chair of quality improvement for the department and director of the women’s health clinics. Nationally, he belongs to the Pacific Coast Reproductive Society and was its President in 1980, the American Society of Reproductive Medicine, the American College of Obstetricians and Gynecologists, and the Pacific Coast Obstetrical and Gynecological Society, having been its President in 2002 and, presently, the Chair of the Society’s Industry Liaison Committee. He has authored multiple, peer-reviewed publications, as well as book chapters. His medical interests include endometriosis, reproductive problems, myomata uteri, sterilization, intrauterine adhesions, and uterine congenital anomalies. Dr. Israel’s outside interests include the completion of ten marathons and classical theater, epitomized by his third appointment to the Board of Directors of A Noise Within, the classical repertory theater in the Los Angeles area.

• Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia. Microorganisms. 2024 Jun 05; 12(6).. View in PubMed
• Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Pain Med. 2023 Mar 01; 24(3):341-350.. View in PubMed
• A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023 03; 12(3):236-248.. View in PubMed
• Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2023 03; 21(3):723-731.e9.. View in PubMed
• Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial. Clin Transl Sci. 2023 01; 16(1):165-174.. View in PubMed
• Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness. J Pain Res. 2023; 16:3529-3543.. View in PubMed
• Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res. 2023; 16:2595-2607.. View in PubMed
• Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials. J Pain Res. 2023; 16:395-406.. View in PubMed
• Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation. Curr Ther Res Clin Exp. 2023; 98:100694.. View in PubMed
• A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Clin Transl Sci. 2022 09; 15(9):2159-2171.. View in PubMed
• First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2022 Feb; 62(2):231-239.. View in PubMed
• Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infect Dis Ther. 2021 Dec; 10(4):2791-2804.. View in PubMed
• P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 Study. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S7.. View in PubMed
• The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. Support Care Cancer. 2021 Sep; 29(9):5209-5218.. View in PubMed
• Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies. J Pain Res. 2021; 14:2687-2697.. View in PubMed
• Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. Am J Clin Dermatol. 2020 Jun; 21(3):421-430.. View in PubMed
• Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag. 2020 Mar; 10(2):73-84.. View in PubMed
• Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020 Feb; 82(2):344-351.. View in PubMed
• Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. Am J Clin Dermatol. 2019 Dec; 20(6):863-871.. View in PubMed
• Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019 02; 180(2):306-314.. View in PubMed
• Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019; 10(1):22-33.. View in PubMed
• Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019 Jan; 80(1):282-285.. View in PubMed
• Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2019; 12:139-150.. View in PubMed
• Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.. View in PubMed
• Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018 Aug; 79(2):287-293.. View in PubMed
• Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. J Pain Res. 2018; 11:1503-1510.. View in PubMed
• Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. J Pain Res. 2018; 11:2509-2516.. View in PubMed
• Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018 Jan; 78(1):81-89.e5.. View in PubMed
• Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017 08; 77(2):372-374.. View in PubMed
• Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. Pain Med. 2017 Aug 01; 18(8):1496-1504.. View in PubMed
• Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract. 2017 07; 17(6):820-828.. View in PubMed
• Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. Antimicrob Agents Chemother. 2017 01; 61(1).. View in PubMed
• An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. J Minim Invasive Gynecol. 2016 Mar-Apr; 23(3):303-8.. View in PubMed
• Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. J Palliat Med. 2015 Jul; 18(7):593-600.. View in PubMed
• Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011 Nov; 42(5):754-60.. View in PubMed
• Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009 Jan-Feb; 7(1):39-46.. View in PubMed
• Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008 May 29; 358(22):2332-43.. View in PubMed
• Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008 May; 35(5):458-68.. View in PubMed
• The relationship between physicians and industry: Faustian or symbiotic? Am J Obstet Gynecol. 2003 Jun; 188(6):1530-40.. View in PubMed
• Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil Steril. 2000 Mar; 73(3):595-7.. View in PubMed
• Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Res. 2021; 10:891.. View in PubMed

• Hendershot, Christian
• Kelley-Quon, Lorraine